Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial

Hillel Panitch, Douglas Goodin, Gordon Francis, Peter Chang, Patricia Coyle, Paul O'Connor, David Li, Brian Weinshenker

Research output: Contribution to journal › Article › peer-review

80 Scopus citations

Fingerprint

Dive into the research topics of 'Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial'. Together they form a unique fingerprint.

Medicine & Life Sciences